All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
Padcev 30mg Injection
Prescription Required
Salt Composition : Enfortumab Vedotin
Manufacturer : ASTELLAS PHARMA INC
Origin of Medicine : India
1 Vial(s)
Introduction to Padcev 30mg Injection
Padcev 30mg Injection contains the active substance Enfortumab vedotin. It is an antineoplastic drug that belongs to the class of antibody-drug conjugates (ADCs). Padcev 30mg Injection is used to treat adults with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy.
Padcev 30mg Injection works by targeting a protein called Nectin-4, which is highly expressed in urothelial cancer cells. The drug delivers a cytotoxic agent known as monomethyl auristatin E (MMAE) directly to the cancer cells. Once inside the cells, MMAE disrupts the microtubule network, leading to cell cycle arrest and cell death. This targeted mechanism helps to destroy cancer cells while minimising damage to healthy tissues. Do not give Padcev 30mg Injection to children or adolescents under the age of 18.
Do not use Padcev 30mg Injection if you are allergic to Enfortumab vedotin or any other ingredients of this medicine. Before starting treatment, inform your doctor if you have a history of kidney problems, heart conditions, eye disorders or if you’ve experienced lung inflammation. Report any symptoms such as difficulty breathing with cough or fever, severe skin peeling, persistent fever, easy bruising or bleeding, unusual tiredness, pale skin, or signs of infection to your healthcare provider promptly.
Uses of Padcev 30mg Injection
Padcev 30mg Injection is used in the treatment of the following:
- Locally advanced or metastatic urothelial cancer in adult patients who have previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy.
Therapeutic Effects of Padcev 30mg Injection
Padcev 30mg Injection works by targeting Nectin-4 on cancer cells and delivering monomethyl auristatin E (MMAE), a cytotoxic agent. Once inside the cancer cells, MMAE interferes with the microtubule network, causing cell cycle arrest and triggering cell death (apoptosis). This targeted mechanism enables the selective destruction of cancer cells while minimizing harm to healthy tissues.
Interaction of Padcev 30mg Injection with other drugs
It is important to inform your healthcare professional about all the medications you are taking, including prescription drugs, over-the-counter medications, nutritional supplements, and herbal products. Some medications may interact with Padcev 30mg Injection, potentially affecting their effectiveness or causing side effects.
More Information about Padcev 30mg Injection
- Keep out of reach of children and pets.
- Store in the original container.
- Store Padcev 30mg Injection in a refrigerator at a temperature 2ºC to 8ºC.
- Do not freeze
How to consume Padcev 30mg Injection
Treatment with Padcev 30mg Injection should be initiated and supervised by a physician experienced in anti-cancer therapies in a hospital setting, with administration in a healthcare facility equipped to manage potential infusion-related reactions. Padcev 30mg Injection is given as an intravenous (IV) infusion under the supervision of a qualified healthcare professional, requiring good venous access before starting treatment. This medication must not be self-administered.
Safety Advices for Padcev 30mg Injection
Pregnancy
It is unsafe to take Padcev 30mg Injection if you are pregnant, as it may cause fetal harm. Consult your doctor for advice and discuss effective contraception methods before starting treatment.
Breast Feeding
It is unknown if Padcev 30mg Injection are safe to take during breastfeeding. Please consult your healthcare provider if you have any concerns.
Lungs
If you have any pre-existing lung conditions, discuss them with your doctor before starting treatment with Padcev 30mg Injection.
Liver
If you have any pre-existing liver conditions, discuss them with your doctor before starting treatment with Padcev 30mg Injection.
Alcohol
It is unknown whether alcohol consumption is safe while you are undergoing Padcev 30mg Injection course. It is recommended to consult your doctor for better guidance.
Driving
It is safe to use Padcev 30mg Injection, as it has no or negligible influence on the ability to drive and use machines. However, if you experience any side effects such as dizziness or blurred vision, consult your doctor before engaging in these activities.
Side Effects of Padcev 30mg Injection
Side effects are unwanted symptoms caused by medicines. Although all drugs can cause side effects, not everyone experiences them.
Common side effects of Padcev 30mg Injection are
- Fatigue
- Nausea
- Decreased appetite
- Diarrhea
- Rash
- Hair loss (alopecia)
- Altered taste (dysgeusia)
- Dry eyes
Serious side effects of Padcev 30mg Injection are:
- Severe Peripheral Neuropathy: May require dose adjustment or discontinuation of treatment.
- Serious Skin Reactions: Including conditions like Stevens-Johnson syndrome and toxic epidermal necrolysis; treatment should be stopped immediately if these occur.
- Hyperglycemia: Can result in ketoacidosis or hyperosmolar hyperglycemic state; requires careful monitoring and management.
Word of Advice
Patients should immediately report any new or worsening symptoms, especially those related to nerve function, skin reactions, or blood sugar levels. Regular communication with healthcare providers is essential for the prompt management of side effects. Adhering to scheduled appointments and monitoring protocols is vital for the safe and effective use of treatment. Additionally, patients should follow their doctor’s advice regarding any necessary adjustments to their therapy.
FAQs
Q 1. What is the use of Padcev 30mg Injection?
Padcev 30mg Injection is primarily used to treat adults with locally advanced or metastatic urothelial carcinoma, which is the most common type of bladder cancer. It is typically prescribed for patients who have previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy. Additionally, enfortumab vedotin may be used in combination with pembrolizumab for patients ineligible for cisplatin-containing chemotherapy.
Q 2. Is Padcev 30mg Injection chemotherapy or immunotherapy?
Padcev 30mg Injection is classified as an antibody-drug conjugate (ADC), which is a form of targeted cancer therapy. It combines a monoclonal antibody that specifically targets Nectin-4—a protein highly expressed in urothelial cancer cells—with a cytotoxic agent that disrupts cancer cell division. This mechanism allows it to deliver chemotherapy directly to cancer cells while sparing healthy tissues. Therefore, it is distinct from traditional chemotherapy and immunotherapy, representing a hybrid approach that leverages aspects of both treatment modalities.
Q 3. What is the success rate of Padcev 30mg Injection?
The effectiveness of Padcev 30mg Injection has been demonstrated in clinical trials. In a pivotal study, enfortumab vedotin achieved an overall response rate (ORR) of 44%, with 12% of patients experiencing a complete response and 32% showing a partial response. The median duration of response was 7.6 months. Furthermore, when combined with pembrolizumab, the ORR increased to approximately 67-68%, with notable improvements in progression-free and overall survival compared to traditional chemotherapy.
Q 4. How much does Padcev 30mg Injection cost?
The cost of Padcev 30mg Injection can vary based on dosage, treatment duration, and insurance coverage. In the United States, the price for a 20 mg vial of Padcev 30mg Injection is approximately Rs. 1,00,000, with a 30 mg vial costing around Rs. 1,55,000. Given that treatment involves multiple vials per dose, the total expense can be substantial. Patients are encouraged to consult with their healthcare providers and insurance companies to understand their financial responsibilities. Additionally, the manufacturer offers assistance programs to help eligible patients manage treatment costs.
Fact Box of Padcev 30mg Injection
Molecule name: Enfortumab vedotin
| Therapeutic class: Antineoplastic Agent |
| Pharmacological class: Antibody-Drug Conjugate (ADC) | Indications: Treatment of adults with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy. |
References
- https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-enfortumab-vedotin-ejfv-metastatic-urothelial-cancer
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761137s019lbl.pdf
- https://fda.report/DailyMed/b5631d3e-4604-4363-8f20-11dfc5a4a8ed
- https://www.padcev.com/about-padcev
Disclaimer
MrMed’s primary intention is to ensure that its consumers get accurate and trustworthy information that is reviewed by experts. The contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
